Spruce Biosciences stock price target raised to $160 from $10 at Leerink

Spruce Biosciences (SPRB): Analyst Raises Price Target Significa

The science behind the therapy that catapulted a biopharma’s stock 1,400% and counting

Why This Biotech Stock Just Rocketed Almost 1,400%

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)